ReviewJournal of the American Society of Nephrology : JASN2021
New 'Antigens' in Membranous Nephropathy.
Review in Journal of the American Society of Nephrology : JASN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 1 synthesis or guideline pooled it, 221 citations in OpenAlex.
- Specific alterations of gut microbiota in patients with membranous nephropathy: A systematic review and meta-analysis.Frontiers in physiology · 2022Pooled it
- A single-center, open label, randomized, controlled study of hydroxychloroquine sulfate in the treatment of low risk PLABMC nephrology · 2024Trial
- Review
- A Clinicopathologic Study of Neural Epidermal Growth Factor-Like 1-Associated Membranous Nephropathy in a Chinese Cohort.Kidney international reports · 2026Article
- Multi-Modal, Machine Learning-Driven Framework Integrating Multi-Omics for Personalized Chronic Kidney Disease Management.Journal of clinical medicine · 2026Review
- Optimization of a Target Antigen Diagnostic Pathway for Membranous Nephropathy.Kidney international reports · 2026Article
- Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous Nephropathy.Kidney international reports · 2026Article
- Complement Profiling in Glomerular Disease: Insights from Laser Microdissection and Mass Spectrometry.Clinical journal of the American Society of Nephrology : CJASN · 2026Review
- Application of the nephrotoxic serum nephritis model in glomerulonephritis research.Molecular medicine (Cambridge, Mass.) · 2026Review
- Clinical profile and outcome of primary membranous nephropathy: A tertiary care center experience from North India.World journal of nephrology · 2026Article
- Protocadherin FAT1-associated membranous nephropathy after hematopoietic stem cell transplantation-a cohort study with clinico-pathological correlations.Clinical kidney journal · 2026Article
- Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy.Kidney international reports · 2026Article
- Characteristics of the gut mycobiome in patients with membranous nephropathy.Scientific reports · 2026Article
- Long-term outcomes in primary membranous nephropathy: a Chinese cohort study with novel target antigen.Frontiers in immunology · 2026Article
- First-line and Second-line Therapy of Zuberitamab in Idiopathic Membranous Nephropathy: A Single-center Retrospective Study.Kidney medicine · 2026Article
- NELL-1-Positive Membranous Nephropathy Following Inhalational Mercury Exposure.Kidney international reports · 2025Article
- Exostosin 1/exostosin 2-associated membranous nephropathy in undifferentiated connective tissue disease: a case report and literature review.BMC nephrology · 2025Review
- Autophagy in the Pathogenesis of Membranous Nephropathy.Kidney medicine · 2025Review
- Time-resolved fluoroimmunoassay improves sensitivity in the diagnosis of primary membranous nephropathy with low phospholipase A2 receptor antibody titer.Scientific reports · 2025Article
- Distinction Between Proliferative Lupus Nephritis and Membranous Lupus Nephritis Based on Inflammation, NETosis, and Glomerular Exostosin.International journal of molecular sciences · 2025Review
85 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Membranous nephropathy (MN) occurs due to deposition of immune complexes along the subepithelial region of glomerular basement membrane. Two previously identified target antigens for the immune complexes, PLA2R (identified in 2009) and THSD7A (in 2014), account for approximately 60% of all MN, both primary and secondary. In the remaining MN, target antigens were unknown. Use of laser microdissection and mass spectrometry enabled identification of new "antigens." This approach led to the identification of four novel types of MN: exotosin 1 (EXT1)- and exotosin 2 (EXT2)-associated MN, NELL1-associated MN, Sema3B-associated MN, and PCDH7-associated MN. Each of these represents a distinct disease entity, with different clinical and pathologic findings. In this review, the structure of the proteins and the clinical and pathologic findings of the new types of MN are discussed. The role of mass spectrometry for accurate diagnosis of MN cannot be overemphasized. Finally, any classification of MN should be made on the basis of the antigens that are detected. Further studies are required to understand the pathophysiology, response to treatment, and outcomes of these new MNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.